Clinical Research Directory
Browse clinical research sites, groups, and studies.
Evaluation of the Impact of Medium-chain Fatty Acids in the Evolution of Newly Diagnosed Mild Cognitive Impairment
Sponsor: Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandria
Summary
Mild cognitive impairment (MCI) is considered the intermediate stage between the changes observed in physiological aging and dementia. Currently, there is no drug therapy, and available drugs offer only minimal benefit on symptoms, only partially slowing the course of the condition. Studies in the literature have investigated the role of omega-3 fatty acids in MCI, and when administered over a period of six months, they appear to improve clinical condition and mood. In addition, medium-chain triglycerides (MCTs) appear to exert an antioxidant function, enhance cognitive ability in patients with MCI or Alzheimer's, and promote deep sleep state.
Official title: Evaluation of the Impact of Medium-chain Fatty Acids in the Evolution of Newly Diagnosed Mild Cognitive Impairment: Prospective Randomized Controlled Trial
Key Details
Gender
All
Age Range
18 Years - 85 Years
Study Type
INTERVENTIONAL
Enrollment
120
Start Date
2024-07-03
Completion Date
2025-11-03
Last Updated
2025-05-04
Healthy Volunteers
No
Conditions
Interventions
Mediterranean-type diet with MCT supplementation
The treatment arm will follow a Mediterranean diet supplemented by daily intake of MCT (30 mL)
Mediterranean-type food regimen using extra virgin olive oil
The arm will follow a Mediterranean diet with an indication to take extra virgin olive oil as the main fat in the diet daily
Locations (1)
Clinical Trial Center
Alessandria, Piedmont, Italy